• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Bolt Biotherapeutics Inc.

    3/24/25 4:31:37 PM ET
    $BOLT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BOLT alert in real time by email
    S-8 1 2025_s-8_evergreen.htm S-8 S-8

    As filed with the U.S. Securities and Exchange Commission on March 24, 2025

    Registration No. 333-

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

    BOLT BIOTHERAPEUTICS, INC.

    (Exact name of Registrant as specified in its charter)

     

     

     

    Delaware

    47-2804636

    (State or other jurisdiction of

    Incorporation or organization)

    (I.R.S. Employer

    Identification No.)

    900 Chesapeake Drive

    Redwood City, California 94063

    (650) 665-9295

    (Address of principal executive offices) (Zip code)

    Bolt Biotherapeutics, Inc. 2021 Equity Incentive Plan

    Bolt Biotherapeutics, Inc. 2021 Employee Stock Purchase Plan

    (Full titles of the plans)

    William P. Quinn

    Chief Executive Officer

    Bolt Biotherapeutics, Inc.

    900 Chesapeake Drive

    Redwood City, California 94063

    (650) 665-9295

    (Name and address of agent for service) (Telephone number, including area code, of agent for service)

    Copy to:

    John T. McKenna

    Cooley LLP

    3175 Hanover Street

    Palo Alto, CA 94304

    (650) 843-5000

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

     

     

     

     

     

     

    Large accelerated filer

    ☐

    Accelerated filer

    ☐

     

     

     

     

    Non-accelerated filer

    ☒

    Smaller reporting company

    ☒

     

     

     

     

     

     

    Emerging growth company

    ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☒


    EXPLANATORY NOTE

    Bolt Biotherapeutics, Inc. (the “Registrant”) is filing this Registration Statement on Form S-8 for the purpose of registering an additional (a) 1,916,984 shares of its common stock, par value $0.00001 per share (the “Common Stock”), issuable to eligible persons under the 2021 Equity Incentive Plan, which Common Stock is in addition to the shares of Common Stock registered on the Registrant’s registration statement on Form S-8s filed on February 5, 2021 (File No. 333-252815), March 30, 2022 (File No. 333-263987), March 29, 2023 (File No. 333-270938), and March 21, 2024 (File No. 333-278141), (the “Prior Form S-8s”), and (b) 383,396 shares of Common Stock issuable to eligible persons under the 2021 Employee Stock Purchase Plan, which Common Stock is in addition to the shares of Common Stock registered on the Prior Form S-8s.

    PART II

    ITEM 3.

    INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE

    Pursuant to General Instruction E to Form S-8, the contents of the Prior Form S-8s are incorporated by reference herein.

    The following documents filed by the Registrant with the Commission are incorporated by reference into this Registration Statement:

    (a) The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed on March 24, 2025, which contains audited financial statements for the Registrant’s latest fiscal year.

    (b) The description of the Common Stock which is contained in a registration statement on Form 8-A filed on February 2, 2021 (File No. 001-39988) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including any amendment or report filed for the purpose of updating such description.

    (c) All other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    ITEM 8.

    EXHIBITS

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Incorporated by Reference

     

     

    Exhibit
    Number

     

    Description

     

    Schedule
    Form

     

    File Number

     

    Exhibit

     

    Filing Date

     

     

     

     

     

     

    4.1

     

    Amended and Restated Certificate of Incorporation of the Registrant.

     

    8-K

     

    001-39988

     

    3.1

     

    2/9/2021

     

     

     

     

     

     

    4.2

     

    Amended and Restated Bylaws of the Registrant.

     

    S-1

     

    333-252136

     

    3.4

     

    1/15/2021

     

     

     

     

     

     

    4.3

     

    Form of common stock certificate of the Registrant.

     

    S-1

     

    333-252136

     

    4.1

     

    1/15/2021

     

     

     

     

     

     

    5.1*

     

    Opinion of Cooley LLP.

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    23.1*

     

    Consent of Independent Registered Public Accounting Firm.

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    23.2*

     

    Consent of Cooley LLP (included in Exhibit 5.1).

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    24.1*

     

    Power of Attorney (see signature page hereto).

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    99.1

     

    2021 Equity Incentive Plan.

     

    S-1/A

     

    333-252136

     

    10.4

     

    2/1/2021

     

     

     

     

     

     

    99.2

     

    2021 Employee Stock Purchase Plan.

     

    S-1/A

     

    333-252136

     

    10.7

     

    2/1/2021

     

     

     

     

     

     

    107*

     

    Filing Fee Table.

     

     

     

     

     

     

     

     

     

    *

    Filed herewith

     


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Redwood City, State of California, on March 24, 2025.

     

     

     

    BOLT BIOTHERAPEUTICS, INC.

     

     

    By:

    /s/ William P. Quinn

     

    William P. Quinn

     

    President, Chief Executive Officer and Chief Financial Officer

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints William P. Quinn and Sarah Nemec, and each of them, as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him or her and in their name, place or stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or his, her or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

     

     

     

     

    Signature

    Title

    Date

     

     

     

    /s/ William P. Quinn

    President, Chief Executive Officer and Chief Financial Officer

    March 24, 2025

    William P. Quinn

    (Principal Executive and Financial Officer)

     

     

     

     

    /s/ Sarah Nemec

    Senior Vice President, Finance

    March 24, 2025

    Sarah Nemec

    (Principal Accounting Officer)

     

     

     

     

    /s/ Brian O’Callaghan

     

    Chairman

     

    March 24, 2025

    Brian O’Callaghan

     

     

     

     

     

     

     

     

     

    /s/ Laura Berner

    Director

    March 24, 2025

    Laura Berner

     

     

     

     

     

    /s/ Jakob Dupont, M.D.

    Director

    March 24, 2025

    Jakob Dupont, M.D.

     

     

     

     

     

     

     

     

    /s/ Kathleen LaPorte

    Director

    March 24, 2025

    Kathleen LaPorte

     

     

     

     

     

     

     

     

     

     

    /s/ Nicole Onetto, M.D.

     

    Director

     

    March 24, 2025

    Nicole Onetto, M.D.

     

     

     

     

     

     

     

     


    Get the next $BOLT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BOLT

    DatePrice TargetRatingAnalyst
    10/20/2025$7.00Buy
    H.C. Wainwright
    1/6/2022$45.00 → $11.00Overweight → Equal-Weight
    Morgan Stanley
    1/6/2022Overweight → Equal-Weight
    Morgan Stanley
    11/10/2021$35.00 → $33.00Outperform
    SVB Leerink
    8/16/2021$34.00 → $35.00Outperform
    SVB Leerink
    More analyst ratings

    $BOLT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

    Initial clinical data for BDC-4182 Phase 1 dose escalation study expected in 3Q 2026  Cash balance of $38.8 million as of September 30, 2025 anticipated to fund key milestones into 2027 REDWOOD CITY, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (NASDAQ:BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the third quarter ended September 30, 2025, and provided a business update. "In the third quarter, we focused on developing BDC-4182, the first next-generation Boltbody™ ISAC in our pipeline. We are actively enrolling patients with gastric and gastroesophageal cancer in the

    11/12/25 4:05:00 PM ET
    $BOLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027

    Initial clinical data for BDC-4182 Phase 1 dose escalation study now expected in 3Q 2026Company is implementing a 50% workforce reduction to extend cash runway into 2027 REDWOOD CITY, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (NASDAQ:BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced an update on the ongoing Phase 1 dose escalation study of BDC-4182, a next-generation Boltbody™ ISAC clinical candidate targeting claudin 18.2, a clinically validated target in oncology. A strong immune response was observed at the initial dose levels and the Company is in the process of modifying the clinical tr

    10/1/25 4:05:00 PM ET
    $BOLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

    Next-generation claudin 18.2 ISAC BDC-4182 now in Phase 1 dose-escalation study Cash balance of $48.5 million as of June 30, 2025 anticipated to fund key milestones through mid-2026 REDWOOD CITY, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (NASDAQ:BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the second quarter ended June 30, 2025, and provided a business update. "In the second quarter we focused on advancing BDC-4182, the first next-generation Boltbody™ ISAC in our pipeline," said Willie Quinn, President and Chief Executive Officer. "We are now conducting a Phase 1

    8/14/25 4:05:00 PM ET
    $BOLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BOLT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President, CEO and CFO Quinn William P. bought $576 worth of shares (125 units at $4.61), increasing direct ownership by 6% to 2,313 units (SEC Form 4)

    4 - Bolt Biotherapeutics, Inc. (0001641281) (Issuer)

    2/4/26 4:32:38 PM ET
    $BOLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Senior VP, Finance and PAO Nemec Sarah bought $576 worth of shares (125 units at $4.61), increasing direct ownership by 10% to 1,415 units (SEC Form 4)

    4 - Bolt Biotherapeutics, Inc. (0001641281) (Issuer)

    2/4/26 4:32:00 PM ET
    $BOLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Senior VP, Finance and PAO Nemec Sarah was granted 23,000 shares and bought $686 worth of shares (125 units at $5.49), increasing direct ownership by 2,827% to 23,943 units (SEC Form 4)

    4 - Bolt Biotherapeutics, Inc. (0001641281) (Issuer)

    10/24/25 7:19:22 PM ET
    $BOLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BOLT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President, CEO and CFO Quinn William P. bought $576 worth of shares (125 units at $4.61), increasing direct ownership by 6% to 2,313 units (SEC Form 4)

    4 - Bolt Biotherapeutics, Inc. (0001641281) (Issuer)

    2/4/26 4:32:38 PM ET
    $BOLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Operating Officer Yonehiro Grant

    4 - Bolt Biotherapeutics, Inc. (0001641281) (Issuer)

    2/4/26 4:32:18 PM ET
    $BOLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Senior VP, Finance and PAO Nemec Sarah bought $576 worth of shares (125 units at $4.61), increasing direct ownership by 10% to 1,415 units (SEC Form 4)

    4 - Bolt Biotherapeutics, Inc. (0001641281) (Issuer)

    2/4/26 4:32:00 PM ET
    $BOLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BOLT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright resumed coverage on Bolt Biotherapeutics with a new price target

    H.C. Wainwright resumed coverage of Bolt Biotherapeutics with a rating of Buy and set a new price target of $7.00

    10/20/25 8:44:35 AM ET
    $BOLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bolt Biotherapeutics downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded Bolt Biotherapeutics from Overweight to Equal-Weight and set a new price target of $11.00 from $45.00 previously

    1/6/22 9:46:37 AM ET
    $BOLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bolt Biotherapeutics downgraded by Morgan Stanley

    Morgan Stanley downgraded Bolt Biotherapeutics from Overweight to Equal-Weight

    1/6/22 7:59:47 AM ET
    $BOLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BOLT
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Bolt Biotherapeutics Inc.

    SCHEDULE 13G/A - Bolt Biotherapeutics, Inc. (0001641281) (Subject)

    11/14/25 4:17:03 PM ET
    $BOLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Bolt Biotherapeutics Inc.

    SCHEDULE 13G/A - Bolt Biotherapeutics, Inc. (0001641281) (Subject)

    11/14/25 4:15:19 PM ET
    $BOLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Bolt Biotherapeutics Inc.

    10-Q - Bolt Biotherapeutics, Inc. (0001641281) (Filer)

    11/12/25 4:08:06 PM ET
    $BOLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BOLT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Bolt Biotherapeutics Inc.

    SC 13G/A - Bolt Biotherapeutics, Inc. (0001641281) (Subject)

    11/14/24 4:19:06 PM ET
    $BOLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Bolt Biotherapeutics Inc. (Amendment)

    SC 13G/A - Bolt Biotherapeutics, Inc. (0001641281) (Subject)

    2/14/24 4:57:08 PM ET
    $BOLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Bolt Biotherapeutics Inc. (Amendment)

    SC 13G/A - Bolt Biotherapeutics, Inc. (0001641281) (Subject)

    2/14/24 4:00:25 PM ET
    $BOLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BOLT
    Leadership Updates

    Live Leadership Updates

    View All

    Bolt Biotherapeutics Announces Changes to its Board of Directors

    REDWOOD CITY, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (NASDAQ:BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced the appointment of Jakob Dupont, M.D., to its Board of Directors. Dr. Dupont brings more than two decades of experience in the field of oncology and immuno-oncology. With the appointment of Dr. Dupont, Executive Partner at Sofinnova Investments, Dr. Jim Healy, M.D., Ph.D., also at Sofinnova, will be stepping down as Lead Independent Director. In addition, Frank D. Lee will be departing the Board and Brian O'Callaghan, CEO of Deep Genomics, will be assuming the role of Chair. "Ja

    9/4/24 4:05:00 PM ET
    $BOLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pacira Appoints Frank D. Lee as Chief Executive Officer

    -- Transformational Leader Brings Three Decades of Global Experience in Pharmaceutical and Biotechnology Product Development and Commercialization -- -- Paul J. Hastings Named Chair of the Board -- -- Dave Stack to Remain in Advisory Role through August 2025 -- TAMPA, Fla., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced that its Board of Directors (the "Board") has appointed Frank D. Lee as Chief Executive Officer and a member of the Board, effective January 2, 2024. As previously announced in September 2023, David Stack will retire from his r

    12/21/23 7:30:00 AM ET
    $BOLT
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bolt Biotherapeutics Appoints Laura Berner to Board of Directors

    REDWOOD CITY, Calif., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (NASDAQ:BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced the appointment of Laura Berner to its Board of Directors effective Dec. 14, 2022. "Laura is an accomplished biopharmaceutical executive with impressive corporate leadership, operations, and business development experience," said Randall Schatzman, Ph.D., Chief Executive Officer of Bolt Biotherapeutics. "As we continue to advance our immuno-oncology pipeline programs in the clinic, Laura brings important strategic perspective from leading and executing more than 50 transact

    12/14/22 4:43:15 PM ET
    $BOLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BOLT
    Financials

    Live finance-specific insights

    View All

    Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

    Next-generation claudin 18.2 ISAC BDC-4182 now in Phase 1 dose-escalation study Cash balance of $48.5 million as of June 30, 2025 anticipated to fund key milestones through mid-2026 REDWOOD CITY, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (NASDAQ:BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the second quarter ended June 30, 2025, and provided a business update. "In the second quarter we focused on advancing BDC-4182, the first next-generation Boltbody™ ISAC in our pipeline," said Willie Quinn, President and Chief Executive Officer. "We are now conducting a Phase 1

    8/14/25 4:05:00 PM ET
    $BOLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 Results and Corporate Updates

    Conference call and webcast on Monday, May 12, 2025, at 2:30 p.m. PT / 5:30 p.m. ET REDWOOD CITY, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (NASDAQ:BOLT), a biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced it will host a key opinion leader (KOL) conference call and webcast featuring Ecaterina Dumbrava, M.D., associate professor of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center and investigator on the Phase 1 dose-escalation clinical study of BDC-3042, on Monday, May 12, 2025 at 2:30 p.m. PT / 5:30 p.m. ET. Dr. Dumbrava will discuss the results from the Phase 1 dose-escalat

    5/8/25 8:00:00 AM ET
    $BOLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bolt Biotherapeutics Reports First Quarter 2024 Results, Announces Strategic Pipeline Prioritization and Changes to Leadership Team

    Refocusing pipeline to Phase 1 Dectin-2 agonist antibody BDC-3042 and next-generation Boltbody™ ISAC platform including new clinical candidate BDC- 4182 targeting Claudin 18.2Bolt to cease further development of trastuzumab imbotolimod (BDC-1001) and reduce workforce by approximately 50%Willie Quinn, Chief Financial Officer, is being appointed as Chief Executive Officer; Randall Schatzman moving to an advisory roleDawn Colburn, Pharm.D., is being promoted to Senior Vice President of Clinical Development to oversee all clinical activities; Edith Perez moving to an advisory roleCash balance of $112.8 million now expected to fund the Company into second half 2026, including generation of clinic

    5/14/24 4:05:00 PM ET
    $BOLT
    Biotechnology: Pharmaceutical Preparations
    Health Care